Release Date: 14 February 2023
Since the approval of the first bispecific antibody in 2009, this novel class of antibodies has taken the market up by the storm as more bispecific antibodies are entering the clinical pipeline and getting approved for a ...
Release Date: 14 February 2023
One of Roche's most recent drugs, Lunsumio, has been approved for the treatment of relapsed or refractory follicular lymphoma. It is a first-in-class bispecific antibody that was approved in 2022 for the indication, and s...
Release Date: 14 February 2023
Roche’s blockbuster Hemlibra has become the global standard of care for the treatment of Hemophilia A. The drug remains one of Roche's best-selling drugs and generated over a billion dollars in revenue once more in ...
Release Date: 13 February 2023
Rare diseases have smaller patient bases when compared to other disease prevalent in the general population, which deters pharmaceutical companies to consider these diseases while developing new drugs. It has been estimat...
Release Date: 08 February 2023
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder wherein blood cells die prematurely and their production in impaired. The disorder affects both red and white blood cells as well as platelets, ...
Release Date: 08 February 2023
The advancements in science and consequently, the treatment approaches, have significantly encouraged the growth and adoption of more modern therapies like immunotherapy. Monoclonal antibodies are one of the most successf...
Release Date: 07 February 2023
The advent of immunotherapy has revolutionized the field of cancer therapy with the goal of harnessing one’s immune system and providing longer lasting cures. Among the existing immunotherapeutic approaches, immune ...
Release Date: 07 February 2023
Oncolytic viruses are one of the most recently emerging therapeutic methods for cancer treatment. These viruses have an affinity for tumor cells and this characteristic is being widely exploited in the cancer therapy doma...
Release Date: 07 February 2023
The continuous research being conducted in identifying new potential targets for cancer treatment has led to the recognition of TIGIT as a possible immune checkpoint target. Undoubtedly, one of the most prevailing achieve...
Release Date: 06 February 2023
Global LAG-3 Inhibitor Market, Drug Sales, Price and Clinical Trials Insight 2028 Report highlights:
Release Date: 02 February 2023
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights:
Release Date: 31 January 2023
With the evolution of clinical research for the identification of more effective treatment methods for cancer, many new methods were introduced into clinical and preclinical trials and are now being used in clinical setti...
Release Date: 25 January 2023
A lot of cancers exploit immune checkpoint deregulation as a defensive measure to evade immune surveillance and proceed towards malignancy. Immune checkpoint blockade enhances clinical results in some cancer patients whos...
Release Date: 16 November 2022
Early in the 20th century, chemotherapy was first used to treat cancer. This came about as a result of intensive study into the best treatments to either slowdown the growth of cancer tumors or, better yet, to eradicate t...
Release Date: 20 October 2022
In the recent years, cancer has rapidly grown to become one of the most life threatening diseases, taking the lives of millions every year. There are several forms of cancer, both genetic and acquired, which affect people...